Enhanced biostability of nanoparticle-based drug delivery systems by albumin corona

Nanomedicine

Volumn 10, Issue 2, 2015, Pages 205-214

  Peng, Qiang ^a   Wei, Xue Qin ^a   Yang, Qin ^b   Zhang, Shu ^a   Zhang, Ting ^b   Shao, Xiao Ru ^a   Cai, Xiao Xiao ^a   Zhang, Zhi Rong ^b   Lin, Yun Feng ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

albumin; drug release; in vivo distribution; metabolism; nanoparticles; protein corona; stability

Indexed keywords

BOVINE SERUM ALBUMIN; CARBON; NANOPARTICLE; NITROGEN; OXYGEN; POLOXAMER; POLY 3 HYDROXYBUTYRATE CO 3 HYDROXYHEXANOATE; POLYMER; SULFUR; UNCLASSIFIED DRUG; COUMARIN DERIVATIVE; DRUG CARRIER;

ARTICLE; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; FLUORESCENCE; MALE; MOUSE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; X RAY PHOTOELECTRON SPECTROSCOPY; ANIMAL; BOVINE; CHEMISTRY; METABOLISM; PROCEDURES;

ANIMALS; CATTLE; COUMARINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; MALE; MICE; NANOPARTICLES; PHOTOELECTRON SPECTROSCOPY; SERUM ALBUMIN, BOVINE;

EID: 84921508122     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.86     Document Type: Article

References (43)

1. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23(11), 1418-1423 (2005).
2. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2(8), 469-478 (2007).
3. Ryu JH, Koo H, Sun IC et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv. Drug Deliv. Rev. 64(13), 1447-1458 (2012).
4. Donaldson K, Duffin R, Langrish JP et al. Nanoparticles and the cardiovascular system: a critical review. Nanomedicine (Lond.) 8(3), 403-423 (2013).
5. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
6. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62(11), 1052-1063 (2010).
7. Peng Q, Zhang ZR, Gong T, Chen GQ, Sun X. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials 33(5), 1583-1588 (2012).
8. Lalatsa A, Lee V, Malkinson JP, Zloh M, Schatzlein AG, Uchegbu IF. A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. Mol. Pharm. 9(6), 1665-1680 (2012).
9. Meyers JD, Doane T, Burda C, Basilion JP. Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond.) 8(1), 123-143 (2013).
10. Peng Q, Sun X, Gong T et al. Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin. Acta Biomater. 9(2), 5063-5069 (2013).
11. Uskokovic V. Entering the era of nanoscience: time to be so small. J. Biomed. Nanotechnol. 9(9), 1441-1470 (2013).
12. Paradise J, Diliberto GM, Tisdale AW, Kokkoli E. Exploring emerging nanobiotechnology drugs and medical devices. Food Drug Law J. 63(2), 407-420 (2008).
13. Schutz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M, Nanoimpactnet C. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond.) 8(3), 449-467 (2013).
14. Yildirimer L, Thanh NT, Loizidou M, Seifalian AM. Toxicology and clinical potential of nanoparticles. Nano Today 6(6), 585-607 (2011).
15. Clift MJ, Bhattacharjee S, Brown DM, Stone V. The effects of serum on the toxicity of manufactured nanoparticles. Toxicol. Lett. 198(3), 358-365 (2010).
16. Perry JL, Reuter KG, Kai MP et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 12(10), 5304-5310 (2012).
17. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdorster G, Mcgrath JL. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30(4), 603-610 (2009).
18. Cedervall T, Lynch I, Foy M et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew. Chem. Int. Ed. Engl. 46(30), 5754-5756 (2007).
19. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105(38), 14265-14270 (2008).
20. Faunce TA, White J, Matthaei KI. Integrated research into the nanoparticle-protein corona: a new focus for safe, sustainable and equitable development of nanomedicines. Nanomedicine (Lond.) 3(6), 859-866 (2008).
21. Lynch I, Dawson KA. Protein-nanoparticle interactions. Nano Today 3, 40-47 (2008).
22. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7(12), 779-786 (2012).
23. Kah JC, Chen J, Zubieta A, Hamad-Schifferli K. Exploiting the protein corona around gold nanorods for loading and triggered release. ACS Nano 6(8), 6730-6740 (2012).
24. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell 'sees' in bionanoscience. J. Am. Chem. Soc. 132(16), 5761-5768 (2010).
25. Salvati A, Aberg C, Dos Santos T et al. Experimental and theoretical comparison of intracellular import of polymeric nanoparticles and small molecules: toward models of uptake kinetics. Nanomedicine 7(6), 818-826 (2011).
26. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, Dawson KA, Aberg C. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J. Am. Chem. Soc. 135(4), 1438-1444 (2013).
27. Wang F, Yu L, Monopoli MP et al. The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomedicine 9(8), 1159-1168 (2013).
28. Rahman M, Laurent S, Tawil N, Yahia L, Mahmoudi M. Protein-nanoparticle interactions. Biophysics 15, 45-63 (2013).
29. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 115(3), 243-250 (2006).
30. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49(36), 6288-6308 (2010).
31. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond.) 6(4), 715-728 (2011).
32. Peng Q, Zhang S, Yang Q et al. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials 34(33), 8521-8530 (2013).
33. Jeong H, Huh M, Lee SJ et al. Photosensitizer-conjugated human serum albumin nanoparticles for effective photodynamic therapy. Theranostics 1, 230-239 (2011).
34. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132(3), 171-183 (2008).
35. Elsadek B, Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J. Control. Release 157(1), 4-28 (2012).
36. Bhogale A, Patel N, Mariam J, Dongre PM, Miotello A, Kothari DC. Comprehensive studies on the interaction of copper nanoparticles with bovine serum albumin using various spectroscopies. Colloids Surf. B Biointerfaces 113, 276-284 (2014).
37. Baek MS, Yu RZ, Gaus H, Grundy JS, Geary RS. In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides 20(6), 309-316 (2010).
38. Aggarwal P, Hall JB, Mcleland CB, Dobrovolskaia MA, Mcneil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61(6), 428-437 (2009).
39. Bhogale A, Patel N, Sarpotdar P et al. Systematic investigation on the interaction of bovine serum albumin with ZnO nanoparticles using fluorescence spectroscopy. Colloids Surf. B Biointerfaces 102, 257-264 (2013).
40. Zhang X, Li L, Xu Z et al. Investigation of the interaction of naringin palmitate with bovine serum albumin: spectroscopic analysis and molecular docking. PLoS ONE 8(3), e59106 (2013).
41. Kusonwiriyawong C, Lipipun V, Vardhanabhuti N, Zhang Q, Ritthidej GC. Spray-dried chitosan microparticles for cellular delivery of an antigenic protein: physico-chemical properties and cellular uptake by dendritic cells and macrophages. Pharm. Res. 30(6), 1677-1697 (2013).
42. Bhattacharyya S, Wang H, Ducheyne P. Polymer-coated mesoporous silica nanoparticles for the controlled release of macromolecules. Acta Biomater. 8(9), 3429-3435 (2012).
43. Zeng X, Tao W, Mei L, Huang L, Tan C, Feng SS. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials 34(25), 6058-6067 (2013).